Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine

NCT01823536 is registered in ClinicalTrials.gov with Novartis Vaccines as lead sponsor.

NCT NCT01823536
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01823536 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Lead sponsor
Novartis Vaccines
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2013
Completion date
June 30, 2014
Enrollment
465 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

meningococcal disease